Long-term survivors and gilteritinib safety beyond 1 year in patients with FLT3-mutated relapsed or refractory acute myeloid leukemia: ADMIRAL trial follow-up

被引：0

作者：

Perl, Alexander E. ^{[1
]}

Martinelli, Giovanni ^{[2
]}

Neubauer, Andreas ^{[3
]}

Berman, Ellin ^{[4
]}

Baer, Maria R. ^{[5
]}

Larson, Richard A. ^{[6
]}

Fathi, Amir T. ^{[7
]}

Yokoyama, Hisayuki ^{[8
]}

Hosono, Naoko ^{[9
]}

Hasabou, Nahla ^{[10
]}

Lu, Qiaoyang ^{[10
]}

Tiu, Ramon V. ^{[10
]}

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[2] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy

[3] Univ Klinikum Giessen & Marburg GmbH, Marburg, Germany

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[6] Univ Chicago, Chicago, IL 60637 USA

[7] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA

[8] Natl Hosp Org, Sendai Med Ctr, Sendai, Miyagi, Japan

[9] Univ Fukui, Fukui, Japan

[10] Astellas Pharma US Inc, Northbrook, IL USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH2021-OR

引用

页码：3 / 4

页数：2

共 50 条

[1] Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R/R AML: ADMIRAL trial follow-up.
Perl, Alexander E.
Martinelli, Giovanni
Neubauer, Andreas
Berman, Ellin
Baer, Maria R.
Larson, Richard A.
Fathi, Amir Tahmasb
Yokoyama, Hisayuki
Hosono, Naoko
Hasabou, Nahla
Lu, Qiaoyang
Bahceci, Erkut
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[2] Follow-up of Patients With FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukaemia in the Phase 3 ADMIRAL Trial
Perl, Alexander E.
Larson, Richard A.
Podoltsev, Nikolai A.
Strickland, Stephen
Wang, Eunice S.
Atallah, Ehab
Schiller, Gary J.
Martinelli, Giovanni
Neubauer, Andreas
Sierra, Jorge
Montesinos, Pau
Recher, Christian
Yoon, Sung-Soo
Hosono, Naoko
Onozawa, Masahiro
Chiba, Shigeru
Kim, Hee-Je
Hasabou, Nahla
Lu, Qiaoyang
Tiu, Ramon
Levis, Mark J.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 6 - 7
[3] Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
McMahon, Christine M.
Perl, Alexander E.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 841 - 849
[4] Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Daver, Naval
Perl, Alexander E.
Maly, Joseph
Levis, Mark
Ritchie, Ellen
Litzow, Mark
McCloskey, James
Smith, Catherine C.
Schiller, Gary
Bradley, Terrence
Tiu, Ramon, V
Naqvi, Kiran
Dail, Monique
Brackman, Deanna
Siddani, Satya
Wang, Jing
Chyla, Brenda
Lee, Paul
Altman, Jessica K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4048 - +
[5] Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
McMahon, Christine M.
Canaani, Jonathan
Rea, Bryan
Sargent, Rachel L.
Qualtieri, Julianne N.
Watt, Christopher D.
Morrissette, Jennifer J. D.
Carroll, Martin
Perl, Alexander E.
BLOOD ADVANCES, 2019, 3 (10) : 1581 - 1585
[6] Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
Hosono, Naoko
Yokoyama, Hisayuki
Aotsuka, Nobuyuki
Ando, Kiyoshi
Iida, Hiroatsu
Ishikawa, Takayuki
Usuki, Kensuke
Onozawa, Masahiro
Kizaki, Masahiro
Kubo, Kohmei
Kuroda, Junya
Kobayashi, Yukio
Shimizu, Takayuki
Chiba, Shigeru
Nara, Miho
Hata, Tomoko
Hidaka, Michihiro
Fujiwara, Shin-Ichiro
Maeda, Yoshinobu
Morita, Yasuyoshi
Kusano, Mikiko
Lu, Qiaoyang
Miyawaki, Shuichi
Berrak, Erhan
Hasabou, Nahla
Naoe, Tomoki
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (11) : 2131 - 2141
[7] Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
Naoko Hosono
Hisayuki Yokoyama
Nobuyuki Aotsuka
Kiyoshi Ando
Hiroatsu Iida
Takayuki Ishikawa
Kensuke Usuki
Masahiro Onozawa
Masahiro Kizaki
Kohmei Kubo
Junya Kuroda
Yukio Kobayashi
Takayuki Shimizu
Shigeru Chiba
Miho Nara
Tomoko Hata
Michihiro Hidaka
Shin-Ichiro Fujiwara
Yoshinobu Maeda
Yasuyoshi Morita
Mikiko Kusano
Qiaoyang Lu
Shuichi Miyawaki
Erhan Berrak
Nahla Hasabou
Tomoki Naoe
International Journal of Clinical Oncology, 2021, 26 : 2131 - 2141
[8] Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial
Perl, A. E.
Martinelli, G.
Cortes, J. E.
Neubauer, A.
Berman, E.
Paolini, S.
Montesinos, P.
Baer, M. R.
Larson, R. A.
Ustun, C.
Fabbiano, F.
Di Stasi, A.
Stuart, R.
Olin, R.
Kasner, M.
Ciceri, F.
Chou, W. -C.
Podoltsev, N.
Recher, C.
Yokoyama, H.
Hosono, N.
Yoon, S. -S.
Lee, J. -H.
Pardee, T.
Fathi, A. T.
Liu, C.
Liu, X.
Bahceci, E.
Levis, M. J.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 295 - 295
[9] Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial
Smith, Catherine C.
Levis, Mark J.
Perl, Alexander E.
Martinelli, Giovanni
Neubauer, Andreas
Berman, Ellin
Montesinos, Pau
Baer, Maria R.
Larson, Richard A.
Chou, Wen-Chien
Yokoyama, Hisayuki
Recher, Christian
Yoon, Sung-Soo
Hill, Jason E.
Rosales, Matt
Bahceci, Erkut
BLOOD, 2019, 134
[10] GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL TRIAL
Perl, A. E.
Martinelli, G.
Cortes, J. E.
Neubauer, A.
Berman, E.
Paolini, S.
Montesinos, P.
Baer, M. R.
Larson, R. A.
Ustun, C.
Fabbiano, F.
Di Stasi, A.
Stuart, R.
Olin, R.
Kasner, M.
Ciceri, F.
Chou, W.
Podoltsev, N.
Recher, C.
Yokoyama, H.
Hosono, N.
Yoon, S.
Pardee, J. Lee T.
Fathi, A. T.
Liu, C.
Liu, X.
Bahceci, E.
Levis, M. J.
HAEMATOLOGICA, 2019, 104 : 2 - 2

← 1 2 3 4 5 →